Imaging software developer Median Technologies is collaborating with Nice University Hospital in France to use artificial intelligence to identify imaging biomarkers for lung cancer screening.
The goal is to enhance diagnoses and provide physicians with new therapeutic decision-making tools based on medical imaging.
A key component is the French multicenter study on circulating tumor cells as a potential screening tool for lung cancer (AIR study), led by the Nice Hospital, in which more than 600 smokers or former smokers with chronic obstructive pulmonary disease are currently enrolled.
Median Technologies' role is to develop new algorithms to identify imaging biomarkers that indicate pulmonary nodule malignity.
